Taihei Ono

<p>Impact of <em>EGFR </em>genotype on the efficacy of osimertinib in <em>EGFR </em>tyrosine kinase inhibitor-resistant patients with non-small cell lung cancer: a prospective observational study</p>

Satoshi Igawa, Taihei Ono, Masashi Kasajima et al. · Cancer Management and Research · 2019 · 24 citations · Full text

Medicine, Oncology, Pharmacology +16

First-line osimertinib for poor performance status patients with EGFR mutation-positive non-small cell lung cancer: A prospective observational study

Satoshi Igawa, Tomoya Fukui, Masashi Kasajima et al. · Investigational New Drugs · 2021 · 21 citations

Medicine, Oncology, Pharmacotherapy +15

Impact of neutrophil-to-lymphocyte ratio in patients with EGFR-mutant NSCLC treated with tyrosine kinase inhibitors

Taihei Ono, Satoshi Igawa, Shintaro Kurahayashi et al. · Investigational New Drugs · 2020 · 19 citations

Medicine, Immunology, Oncology +15

Evaluation of osimertinib efficacy according to body surface area and body mass index in patients with non‐small cell lung cancer harboring an <i>EGFR</i> mutation: A prospective observational study

Taihei Ono, Satoshi Igawa, Takahiro Ozawa et al. · Thoracic Cancer · 2019 · 18 citations · Full text

Medicine, Oncology, Pharmacology +15

A Prospective Observational Study of Osimertinib for Chemo-Naive Elderly Patients with EGFR Mutation-Positive Non-Small Cell Lung Cancer

Satoshi Igawa, Masashi Kasajima, Taihei Ono et al. · Cancer Management and Research · 2021 · 14 citations · Full text

Medicine, Oncology, Pharmacology +17